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Introduction
Diabetes mellitus (DM) is a metabolic dysfunction characterized by a defect in the action and/or secretion of insulin resulting in hyperglycemia. The estimate is that there are more than 150 million in the world 1 .
Diabetic cystopathy (DC) is one of the most common complications of DM involving high costs for the health system.
Dysfunctions of the urinary tract have been identified in more than 50% of diabetic patients even when they are asymptomatic 2 .
The classical symptoms of DC are reduced bladder sensitivity, reduced detrusor contractility and incomplete bladder emptying resulting in post-voiding residue 3, 4 . In addition to these complications, DM also induces changes in bladder mass and in the composition of the parenchyma and compliance of the organ 2 .
However, the classical symptoms are not always observed in all diabetic patients, with a wide variety of symptoms commonly
occurring. There was also demonstrated increased urinary frequency associated with bladder hyperactivity in the initial phase of the disease 5 .
Nitric oxide (NO) acts as a non-adrenergic and noncholinergic neurotransmitter in the bladder and the urethra and promotes the relaxation of smooth muscle fibers by the activation of guanylate cyclase, which is responsible for the transformation of GMP to GMPc. Since sildenafil citrate inhibits the activity of phsphodiesterase-5, which promotes GMPc hydrolysis, there is an increase in this compound. Thus, there is a scientific basis for the use of sildenafil not only for the treatment of erectile dysfunction, but also for detrusor hyperactivity 6 .
The objective of the present study was to assess the effects of sildenafil citrate on the function of the lower urinary tract after six weeks of DM induction.
Methods
All procedures involving animals were in accordance The animals were house in collective cages at room temperature on sunlight cycle, with water and ration ad libitum. Diabetes mellitus (DM) was induced at random in 14 rats by a single intraperitoneal injection of alloxan, 40 mg/kg body weight, dissolved in 0.05 M sodium citrate, pH 4.5, at 4 o C. Blood glucose level was determined by the glucose oxidation method (Accu-Check Complete System, Roche) 72 hours after alloxan administration. All diabetic animals had a glycemia level of more than 300 mg/dl.
Six weeks after the induction of DM, the animals were divided at random into two groups, i.e., animals studied six weeks after the induction of diabetes (group 3, n=9) and five animals studied six weeks after the induction of diabetes and treated with sildenafil citrate injected intraperitoneally at the dose of 1 mg/kg weight. Urodynamic evaluation was performed 1 hour after the administration of this medication.
The remaining healthy animals were divided into two groups: group 1 (n=9) no treatment, and group 2 (n=6) healthy animals treated with sildenafil citrate.
All animals were kept under ideal conditions on a 12
hour light cycle with free access to water and ration.
Urodynamic evaluation
The evaluation was performed after intraperitoneal anesthesia with urethane (1.25 mg/kg weight) 6 . After suprapubic Each animal was submitted to urodynamic evaluation for 30 minutes and sacrificed while still under the effect of anesthesia.
Data were analyzed based on the following parameters:
mean urethral pressure during detrusor contraction (UPC) and mean urethral pressure during bladder filling (UPF).
Statistical analysis
The obtained values of parameters of cystometry and urethral pressure recordings were evaluated using nonparametric Kruskal
Wallis with Dunn post-test, considering significant differences with a p<0.05. The results were expressed as mean ± standard deviation (SD). Calculations were made using GraphPad Prism 3.02.
Results
The mean serum glucose level of female rats with alloxan-induced diabetes was 400.0 mg/dl, as opposed to mean pre-induction levels of 100 mg/dl.
Functional evaluation
No significant difference was observed between groups in the analysis of MMP (p=0.633), BC (p=0.1003), F (p= .5717) or TF (p=0.746) ( Table 1) .
Urethral pressure during bladder filling (UPF)
There was no significant difference between groups in this variable. However, the p value was found to be quite close to the level of significance adopted (p=0.07). 
Bladder contraction time (TC)
There was a significant increase in this variable in the group of diabetic rats. The post hoc Dunn test revealed that this difference occurred between G1 and G3 animals (p=0.0278)*.
Urethral pressure during detrusor contraction (UPC)
There was a significant difference between G1 and G2 (p=0.0121)* and between G1 and G3 (p=0.001) (Figure 1 ). In agreement with the present study, other authors have reported that female diabetic rats with a six week follow-up have a prolonged time of detrusor contraction compared to normal rats 8 .
In the cited study, the objective of the authors was to assess the effects of diabetes on the activity of the outer sphincter of the urethra (OSU) with a follow-up time of six and twenty weeks.
They demonstrated that there is a markedly increased of the OSU activity during micturition. However, OSU activity proved to be stable during the phase of bladder filling 8 .
The sympathetic nerves at the S2 to S4 medullary level Yang et al. 13 observed a significant deficit of urethral relaxation in rats by five to 10 weeks after induction of DM.
They also observed that the increase in urethral resistance was due in part to the presence of vesical-sphincter dyssynergia (VSD), present in 30% of the diabetic rats studied and absent in all healthy rats. VSD was clearly demonstrated by the increased activity of tonic fibers of the external urethral sphincter and the cited study also revealed that treatment with alphabungarotoxin, a blocker of skeletal muscle activity, promoted a marked reduction of the urethral pressor profile in diabetic rats, suggesting that external urethral sphincter activity may be dysfunctional in the voiding cycle of DM.
Furthermore, the same study demonstrated that, in addition to urethral dysfunction of the external sphincter, there is also a reduction of relaxation of urethral smooth muscle mediated by nitric oxide (NO) and sensitization of urethral smooth muscle to alpha-adrenergic agonists. These last two effects are more pronounced over a more prolonged time of diabetes induction 13 .
NO is the major neurotransmitter that mediates the relaxation of urethral smooth muscle during micturition in rats and in other species 14 . Changes in NO production are involved in dysfunction of the penis, bladder and other organs. However, the involvement of changes in the production and efficacy of NO in urethral dysfunction due to diabetes has been little documented in the literature. These recently studies demonstrated the impact of sildenafil on micturition behavior and urethral tone, and that irrespective of the hormonal status, sildenafil decreased leak point pressure by a nNOS-mediated mechanism [15] [16] [17] .
The findings of the present study suggest that in diabetic female rats the high levels of urethral pressure during micturition may be an important factor for the understanding of the physiopathology of DC.
Sildenafil citrate promoted partial relaxation of the urethra of about 35.3%. Other study demonstrated significant relaxation of the bladder strips by 37.3% and of the urethra strips by 44.0% 15 . This finding suggests that the phosphodiesterase-5 inhibitors had relaxant effects on the urethra smooth muscle.
The autor suggest that PDE-E inhibitors could be applied as an effective treatment ofr BPH and LUTS.
NO pathway contributes to the control of urethral function in diabetes, but is not the only pathway involved in this effect.
There are other factors that control urethral function, such as the autonomic fibers, which provide the nerve supply for the urethra, and muscle fibers which, when altered, may promote VSD 13 . We may also cite the neutrotransmitters that mediate the relaxation of urethral smooth muscles such as carbon monoxide, vasoactive intestinal polypeptide, adenosine triphosphate, noradrenaline, and beta-adrenergic receptors.
Sildenafil citrate has been reported to act both on the bladder and on the bladder neck. In rats chronically treated (six weeks) with sildenafil citrate by the oral route, with treatment starting at the time of induction of mild obstruction of the bladder neck, there was prevention of hypertrophy of the detrusor muscle, detrusor hyperactivity and collagen deposition in the lamina propria and in smooth muscle, characteristic of bladder outlet obstruction 18 .
In humans, daily Phospdiesterase 5 inhibitors (PDE5Is) alone or in association with alpha-blockers AB also demonstrate efficacy in this indication 19 .
In the present study, the treatment was acute, with the administration of a single dose of sildenafil citrate and urodynamic evaluation performed one hour later. Sildenafil citrate acted by partially reducing urethral pressure during micturition.
We did not observe changes in maximum detrusor contraction pressure after six weeks of alloxan-induced diabetes.
Studies about this topic are controversial, with reports of increased 20, 21 , reduced 22, 23 or unchanged 24 contractile responses.
The differences between reports may be due to different methodologies, differences in animal gender and variation in the time of diabetes induction. Although there is wide variability in the results of these studies, it can be seen that DM significantly changes the function of urethral smooth muscle, although little is effectively known about the possible mechanisms involved in these alterations.
Conclusion
Diabetes mellitus initially promotes urethral dysfunction characterized by increased urethral pressure during micturition.
Sildenafil citrate acted by partially reducing the urethral pressure during micturition.
